AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
05 Janeiro 2024 - 3:32PM
Business Wire
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the
“Company”) today announced that shareholders have elected all four
of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan,
Thomas K. Equels and William M. Mitchell, at the Company’s 2023
Annual Meeting of Stockholders (the “2023 Annual Meeting”) held
today.
AIM issued the following statement:
“We would like to thank our shareholders for their support and
engagement throughout this process. Our Board and management team
are fully committed to our mission of delivering life-saving
treatments for unmet patient needs and creating value for
shareholders. We look forward to achieving additional near-term
clinical milestones as we build on our recent significant momentum
and will keep investors updated on an ongoing basis.”
The results announced today are considered preliminary until
final results are tabulated and certified by the independent
Inspector of Elections. The Company will file the final voting
results on a Form 8-K with the Securities and Exchange
Commission.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the
research and development of therapeutics to treat multiple types of
cancers, immune disorders and viral diseases, including COVID-19.
The Company’s lead product is a first-in-class investigational drug
called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3
agonist immuno-modulator with broad spectrum activity in clinical
trials for globally important cancers, viral diseases and disorders
of the immune system.
For more information, please visit aimimmuno.com and connect
with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “continue,” “believe,” “potential,” “upcoming” and
other variations thereon and similar expressions (as well as other
words or expressions referencing future events or circumstances)
are intended to identify forward-looking statements. Many of these
forward-looking statements involve a number of risks and
uncertainties. The Company urges investors to consider specifically
the various risk factors identified in its most recent Form 10-K,
and any risk factors or cautionary statements included in any
subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities
and Exchange Commission (the “SEC”). You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Among other things, for
those statements, the Company claims the protection of safe harbor
for forward-looking statements contained in the PSLRA. The Company
does not undertake to update any of these forward-looking
statements to reflect events or circumstances that occur after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240105031286/en/
Investor Contact: JTC Team, LLC Jenene Thomas
833-475-8247 AIM@jtcir.com Media Contact: Longacre Square
Partners Joe Germani / Miller Winston AIM@longacresquare.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024